Mga aktibong sangkap na parmasyutiko
| Progestogen at estrogen | |||
| Pangalan ng produkto | Pagtukoy | Inaprubahan | CAS Hindi. |
| Progesterone | CP/EP/USP/JP | CEP/EU-GMP/FDA | 57-83-0 |
| Pagbubuntis | In-house |
Kosher | 145-13-1 |
| Medroxyprogesterone Acetate | CP/EP/USP/JP | DMF/GMP | 71-58-9 |
| Megestrol acetate | CP/EP/USP | DMF sa proseso | 595-33-5 |
| Mifepristone | CP/IP | DMF/GMP | 84371-65-3 |
| Cyproterone acetate | CP/EP/IP/KP | CEP/TGA/EU-GMP | 427-51-0 |
| Levonorgestrel | CP/EP/USP/IP | CEP/GMP | 797-63-7 |
| Norethisterone |
CP/EP/USP/JP |
DMF sa proseso |
68-22-4 |
| Norethisterone acetate |
EP/USP |
DMF sa proseso |
51-98-9 |
| Norethisterone Enanthate |
In-house |
Sa ilalim ng R&D |
3836-23-5 |
| Drospirenone | EP/USP | DMF | 67392-87-4 |
| Gestodene | CP/EP | DMF/GMP | 60282-87-3 |
| Estradiol | CP/EP/USP/KP | DMF/GMP/WC | 35380-71-3 |
| Estriol | CP/EP/USP | Sa ilalim ng R&D | 50-27- 1 |
| Ethinyl estradiol | CP/EP/USP | GMP | 57-63-6 |
| Estradiol Valerate | CP/EP/USP/KP | DMF | 979-32-8 |
| Estradiol Cypionate |
USP | DMF sa proseso |
313-06-4 |
| Promestriene |
In-house |
Sa ilalim ng R&D |
39219-28-8 |
| Tibolone | CP/EP | DMF/GMP | 5630-53-5 |
| Dienogest | EP | CEP/GMP | 65928-58-7 |
| Fulvestrant | EP/USP | Sa ilalim ng R&D | 129453-61-8 |
| Exemestane | CP/EP/USP | Sa ilalim ng R&D | 107868-30-4 |
| Androgen | |||
| Pangalan ng produkto | Pagtukoy | Inaprubahan | CAS Hindi. |
| Finasteride | CP/EP/USP | CEP/FDA/PMDA/GMP | 98319-26-7 |
| Dutasteride | EP/USP | CEP/FDA | 164656-23-9 |
| Abiraterone acetate | CP/USP | DMF/GMP/WC | 154229-18-2 |
| Darolutamide |
In-house |
Sa ilalim ng R&D |
1297538-32-9 |
| Testosterone | CP/EP/USP | CEP/FDA/WC | 58-22-0 |
| Testosterone Undecanoate | CP | DMF/WC | 5949-44-0 |
| Testosterone Cypionate | USP | DMF | 58-20-8 |
| Testosterone Enanthate |
USP/JP | Sa ilalim ng R&D |
315-37-7 |
| Testosterone Propionate |
CP/EP/USP/JP |
Sa ilalim ng R&D |
57-85-2 |
| DHEA | FP/In-house | Dmf/wc/kosher | 53-43-0 |
| Clascoterone | In-house | DMF sa proseso | 19608-29-8 |
| Cortical hormone | |||
| Pangalan ng produkto | Pagtukoy | Inaprubahan | CAS Hindi. |
| Budesonide | CP/EP/USP/JP | CEP/FDA/GMP | 51333-22-3 |
| Desonide | CP/USP | DMF/GMP | 638-94-8 |
| Eplerenone | EP | Cep sa proseso | 107724-20-9 |
| Methylprednisolone | CP/EP/USP/JP | DMF/GMP | 83-43-2 |
| Methylprednisolone Hemisuccinate | CP/EP/USP | DMF/GMP | 2921-57-5 |
| Fluticasone Propionate | CP/EP/USP | DMF | 80474- 14-2 |
| Fluticasone furoate | CP/EP | DMF sa proseso | 397864-44-7 |
| Mometasone Furoate |
CP/EP/USP |
DMF sa proseso |
Anhydrous (83919-23-7) Monohydrate (141646-00-6) |
| Deflazacort |
In-house |
Sa ilalim ng R&D |
14484-47-0 |
| Iba | |||
| Pangalan ng produkto | Pagtukoy | Inaprubahan | CAS Hindi. |
| Oxcarbazepine | CP/EP/USP/IP | CEP/FDA/GMP | 28721-07-5 |
| Eslicarbazepine acetate | CP/USP | DMF | 236395- 14-5 |
| GANCICLOVIR | CP/EP/USP | DMF/GMP | 82410-32-0 |
| Valganciclovir Hydrochloride | USP/EP | Cep sa proseso | 175865-59-5 |
| Oseltamivir phosphate | CP/EP/USP | DMF | 204255- 11-8 |
| Baloxavir Marboxil | In-house | Sa ilalim ng R&D | 1985606-14-1 |
| Revefenacin | In-house | DMF | 864750-70-9 |
| Mirabegron | CP/EP | DMF | 223673-61-8 |
| Vibegron |
In-house |
Sa ilalim ng R&D |
1190389-15-1 |
| Escitalopram oxalate | CP/EP/USP | DMF sa proseso | 219861-08-2 |
| Citalopram hydrobromide |
CP/EP/USP |
DMF sa proseso |
59729-32-7 |
| Cariprazine Hydrochloride | In-house | DMF | 1083076-69-0 |
| Lasmiditan succinate | In-house | DMF | 439239-92-6 |
| Luliconazole | In-house | DMF | 187164-19-8 |
| Nintedanib esylate |
In-house |
FDA/DMF/WC |
656247-18-6 |
| Apalutami | In-house | DMF | 956104-40-8 |
| Tadalafil | CP/EP/USP | Sa ilalim ng R&D | 171596-29-5 |
| Relugolix | In-house | DMF sa proseso | 737789-87-6 |
| Ruxolitinib phosphate |
In-house |
DMF sa proseso |
1092939-17-7 |
| Abemaciclib |
In-house |
Sa ilalim ng R&D |
1231929-97-7 |
| Phloroglucinol | CP/EP | DMF | 108-73-6 |
| 1,3,5-trimethoxybenzene |
Cp/in-house |
GMP |
621-23-8 |
| Ursinoxycholic acid | EP/USP/JP | Sa ilalim ng R&D | 128-13-2 |
| Tauroursinoxycholic acid |
In-house |
Sa ilalim ng R&D |
14605-22-2 |
| Kolesterol |
CP/EP/USP/JP |
Sa ilalim ng R&D |
57-88-5 |
| Omega-3-acid ethyl eter 90 |
EP/USP |
DMF sa proseso |
—— |
| Medium-chain triglycerides |
CP/USP/EP |
DMF |
—— |
| Benzalkonium chloride |
USP/EP/JP |
Cep sa proseso |
8001-54-5 |
| Langis ng oliba (para sa iniksyon) |
CP/USP/EP/JP |
DMF sa proseso |
8001-25-0 |
| Egg phospholipids (para sa iniksyon) |
CP/USP/EP |
DMF |
93685-90-6 |
| Meryenda |
In-house |
DMF sa proseso |
203787-91-1 |
Ang Lasmiditan Succinate ay mayroong In-house na detalye. Inaprubahan ng DMF.
Ang Cariprazine hydrochloride ay may In-house na detalye. Inaprubahan ng DMF.
Ang Mirabegron ay may In-house na detalye. Inaprubahan ng DMF..
Ang Fulvestrant ay may mga detalye ng EP at USP.
Ang luliconazole ay may pagtutukoy sa bahay, Inaprubahan ang DMF.